Sensitivity of FDG PET, GLUT1 expression and proliferative index in bronchioloalveolar lung cancer

Nuclear Medicine Communications

Volumn 28, Issue 3, 2007, Pages 173-177

  Khandani, Amir H ^a,b   Whitney, Kathleen D ^a   Keller, Steven M ^a   Isasi, Carmen R ^a   Donald Blaufox, M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchioloalveolar lung cancer; FDG; Glucose transporter; PET; Proliferating cell nuclear antigen; Proliferative index

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; PROTEIN ANTIBODY;

ARTICLE; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; LUNG LAVAGE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; RADIOSENSITIVITY; WORLD HEALTH ORGANIZATION;

BRONCHIAL NEOPLASMS; CELL PROLIFERATION; CESIUM; EPITHELIAL CELLS; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LUNG; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROLIFERATING CELL NUCLEAR ANTIGEN; RADIOPHARMACEUTICALS; STROMAL CELLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33846703626     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328013ebc5     Document Type: Article

References (13)

1. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137-142.
2. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38:261-266.
3. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002; 29:1166-1173.
4. Higashi K, Ueda Y, Sakurai A, Wang XM, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with 18-F FDG uptake in non-small cell lung cancer. Eur J Nucl Med 2000; 27:1778-1785.
5. Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41:85-92.
6. Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005; 7:369-379.
7. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997; 74:189-192.
8. Patz Jr EF, Lowe VJ, Hoffman JM, Paine SS, Burrowes P, Coleman RE, Goodman PC. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1999; 188:487-490.
9. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.
10. Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998; 39:1727-1735.
11. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol 2000; 174:1005-1008.
12. Gospodarowicz D, Greenburg G, Birdwell CR. Determination of cellular shape by the extracellular matrix and its correlation with the control of cellular growth. Cancer Res 1978; 38:4155-4171.
13. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983; 49:636-649.